Alberta Reappraising AIDS Society
David Crowe, President
Phone: +1-403-289-6609
Fax: +1-403-206-7717
Email: David.Crowe@aras.ab.ca

Kathleen Newell, Treasurer
Box 61037, Kensington Postal Outlet
Calgary, Alberta T2N 4S6
Canada
Office
Phone: +1-403-220-0129
Email: aras@aras.ab.ca
Web: noaids.ca

Concerns about HAART (Highly Active Anti-Retroviral Therapy)

HAART is the therapy, composed of multiple anti-HIV drugs, that is prescribed to many HIV-positive people, even before they develop symptoms of AIDS (and without considering that many will never develop these symptoms). The therapy usually includes one nucleoside analog (DNA chain terminator), one protease inhibitor and either a second nucleoside analog (“nuke”) or a non-nucleoside reverse transcription inhibitor (NNRTI).

The quotes are categorized as:

  • Acceptance of HAART
  • Adherence
  • Adverse Effects, in General
  • Adverse Effects with Nucleoside Analogs (‘Nukes’)
  • Auxiliary Therapy
  • Blood Disorders
  • Bone Disease
  • Cancer
  • AIDS Drugs cause Heart Disease
  • Ineffectiveness or Lack of Proof of Effectiveness, often Combined with Toxicity
  • Immune Restitution Disease (IRD) or Immune Restoration Inflammatory Syndrome (IRIS)
  • HAART is Nephrotoxic, Causing Renal (Kidney) Damage
  • Liver Damage
  • HAART for a Life Time (not a Good Time)?
  • Metabolic
  • HAART and Mitochondria
  • Muscle Damage with HAART
  • Neurological Damage
  • Nevirapine
  • Non-HIV Benefits of HAART
  • Health Without Toxic Therapies
  • Post-Exposure Prophylaxis
  • Adverse Effects, Mothers & Children
  • Adverse Effects with Protease Inhibitors
  • Resistance to Therapy
  • HAART and Skin Problems
  • HAART Usage Trends

    • Feedback

    We appreciate your comments, feedback, questions and suggestions for improvements to this site. Click here to send us a message.

    © Copyright February 2, 2010: Alberta Reappraising AIDS Society